Johnson & Johnson stock (US4781601046): cancer trial data spotlight oncology pipeline

Johnson & Johnson shares on the NYSE are in focus after the U.S. healthcare group reported pivotal Phase 1b/2 OrigAMI-4 head and neck cancer data and final Phase 3 PROTEUS prostate cancer results around ASCO 2026, underscoring the strategic role of its oncology pipeline.

Johnson & Johnson shares on the New York Stock Exchange traded in the low USD 150s on 05/31/2026, leaving the U.S. healthcare heavyweight in focus as the company used the ASCO 2026 meeting in Chicago to highlight new oncology data from multiple late-stage trials, according to Nasdaq price data as of 05/31/2026.

The New Brunswick, New Jersey-based group said on 05/31/2026 that the Phase 1b/2 OrigAMI-4 study of RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) in previously treated advanced head and neck squamous cell carcinoma delivered strong and durable responses, with more than one-third of responders achieving complete responses and the median duration of response not yet reached, as detailed in a company press release on 05/31/2026.Johnson & Johnson press release as of 05/31/2026

The U.S. group also submitted a supplemental Biologics License Application to the Food and Drug Administration seeking approval for subcutaneous amivantamab in head and neck cancer, building on a Breakthrough Therapy Designation in this indication, according to the same 05/31/2026 statement.Johnson & Johnson press release as of 05/31/2026

Separately on 05/31/2026, Johnson & Johnson reported final results from the Phase 3 PROTEUS trial in high-risk localized or locally advanced prostate cancer, showing that investigational use of ERLEADA (apalutamide) plus androgen deprivation therapy before and after surgery reduced the risk of metastasis or death by 20 percent versus control and cut the risk of disease recurrence or death by 29 percent, according to a release carried on 05/31/2026.PR Newswire as of 05/31/2026

The company noted that patients in PROTEUS receiving apalutamide plus hormone therapy were nine times more likely to have minimal residual cancer in the prostate after surgery compared with control, while time to distant metastasis also improved with a hazard ratio of 0.68 in the final analysis, reinforcing the potential of this perioperative regimen in a curative-intent setting.PR Newswire as of 05/31/2026

ERLEADA is already approved in the United States for metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer, but apalutamide plus hormone therapy in the perioperative setting has not yet been approved by regulators, so the new data feed into future potential label-expansion discussions rather than immediate commercial changes.PR Newswire as of 05/31/2026

In Germany, Johnson & Johnson can also be traded on platforms such as Tradegate in euros, giving local investors access to the U.S.-listed healthcare stock alongside its primary NYSE listing.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Johnson & Johnson
• Sector/industry: Healthcare, pharmaceuticals and medical technology
• Headquarters/country: New Brunswick, United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Innovative pharmaceuticals, medical devices, consumer health products
• Home exchange/listing venue: New York Stock Exchange (JNJ)
• Trading currency: USD

Johnson & Johnson: core business model

Johnson & Johnson operates as a diversified U.S. healthcare group with a strong focus on innovative medicines and medical technologies, generating most of its revenue from branded pharmaceuticals, surgical and interventional devices, and selected consumer health categories.

What banks and research houses say about Johnson & Johnson

No verified analyst coverage was identified at the time of publication.

Conclusion

The clustering of new RYBREVANT FASPRO and ERLEADA data at ASCO 2026 keeps Johnson & Johnson's oncology franchise in the spotlight and underscores the U.S. group's ambition to expand into additional tumor types and treatment settings. For equity investors, the latest readouts add clinical detail that could influence how the market values the company's late-stage pipeline over time, even though regulatory decisions and commercial uptake remain medium-term factors.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.